Microbial expression systems are crucial in developing innovative medicines and expanding development pipelines due to the broad range of molecule formats that can be obtained using this technology. However, this approach can be challenging as it requires a variety of manufacturing processes to handle these diverse molecule formats. This is where collaboration with an experienced organization comes into play. Boehringer Ingelheim, known for its proficiency in this technical domain, has a proven track record with 19 commercial microbial products and successful audits and regulatory compliance. The company's commitment to quality and flexibility in implementing production processes make it a reliable partner. Its technology-platform neutrality also simplifies technology and process transfers. Fill out the form below to read the full report.

This webcast features: Artur Stanczak, Field Application Specialist, Process Chromatography, Bio-Rad Laboratories. Large molecule purification presents significant challenges due to their considerable size. For instance, Immunoglobulin M (IgM) molecules, ranging from 900 to 1,000 kD, play pivotal roles in mammalian immune responses and find extensive applications in diagnostics and therapeutics. Purification of such molecules is particularly intricate owing to several factors including their weak Protein A binding sites, limited dynamic binding capacity, and slow diffusion rates. Moreover, IgMs exert notable effects on chromatographic purification processes. Their inability to penetrate small pores necessitates higher pore volume utilization, resulting in sluggish diffusion and mass transfer kinetics within traditional chromatography resins. Consequently, this diminishes binding capacity and resolution, thereby complicating purification efforts. This webinar will delve into innovative strategies to sur...